Optimer Pharmaceuticals Inc. (OPTR) is in the Pharma Industry

• Sort by
• View by Content Type

• Optimer Reports Additional Data on Investigational Compound OPT-80 at Anaerobe 2008 Congress

  - Epidemic Hypervirulent Strain BI/NAP1/027 Was Well Represented in the Phase 2A Study - SAN DIEGO -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) presented new data from its Phase 2A clinical study of OPT-80 finding a 42% presence of the super toxin-producing strain of C. difficile known as BI/NAP1/027 strain...

  Research articles 2008-06-26

  Tags: infection, Optimer Pharmaceuticals Inc., SECURITY, strain, U.S. Congress

• Optimer Pharmaceuticals, Inc. Q4 2007 Earnings Call Transcript

  Question-and-Answer Session Operator Thank you, sir. Operator instructions. We will take our first question from Adam Cutler with Canaccord Adams. Adam Cutler – Canaccord Adams Hi, thanks for taking the question. I’m wondering on OPT-80 if you can give us a sense of, in...

  Earnings calls 2008-04-27

  Tags: Optimer Pharmaceuticals Inc.

• Optimer Pharmaceuticals to Present at the 19th Annual Piper Jaffray Health Care Conference

  SAN DIEGO -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) announced today that the Company plans to present on Tuesday, November 27th during the 19th Annual Piper Jaffray Health Care Conference at The Pierre Hotel at 9:30 a.m. ET. An audio webcast of the Piper Jaffray Conference will be available live and...

  Research articles 2007-11-20

  Tags: Benefits, conference, HEALTHCARE, Optimer Pharmaceuticals Inc., SOFTWARE, U.S. Bancorp Piper Jaffray Inc.

Additional Resources

• Optimer Pharmaceuticals to Present at the 20th Annual Piper Jaffray Health Care Conference

  SAN DIEGO, CA -- Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) is scheduled to present at the 20th Annual Piper Jaffray Health Care Conference at The New York Palace in New York City on December 2, 2008, 12:00 p.m. Eastern Time. A live audio webcast of this presentation will be accessible...

  Articles 2008-11-25

• Beacon Equity Issues Technical Trade Alerts on Market Movers: OPTR, RNWK, ARQL, CROX, WRES, LWSN

  DALLAS, Nov. 12 /PRNewswire/ -- BeaconEquity.com announces the availability of Trade Alerts on stocks making news today. Investors can view all of the daily trading notes for free by visiting: http://www.beaconequity.com/m Today's Trade Alerts include: Optimer Pharmaceuticals Inc. , RealNetworks Inc. , ArQule Inc. ,...

  Articles 2008-11-12

• Optimer Pharmaceuticals Reports Positive Data from its North American Phase 3 CDI Study of OPT-80

  OPT-80 Achieves its Primary Endpoint of Clinical Cure with a Lower Recurrence Rate vs. Vancocin([R]) SAN DIEGO -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) today released positive top-line results from a pivotal Phase 3 clinical study of the Company's lead anti-infective drug candidate, OPT-80, in patients with Clostridium difficile...

  Articles 2008-11-10

• Optimer Pharmaceuticals Reports Third Quarter 2008 Financial Results

  SAN DIEGO -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced its financial results for the third quarter ended September 30, 2008. Optimer reported a net loss for the third quarter of 2008 of $9.2 million, or $0.31 per share, compared to a net loss of $6.5 million, or $0.28 per share,...

  Articles 2008-11-05

• Optimer Pharmaceuticals to Present at Oppenheimer Annual Healthcare Conference

  SAN DIEGO -- Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) is scheduled to present at Oppenheimer's Nineteenth Annual Healthcare Conference at the Waldorf-Astoria Hotel in New York City on November 3, 2008, 8:40 a.m. Eastern Time. A live audio webcast of this presentation will be accessible on the Company's website at...

  Articles 2008-10-29

• Data from Optimer Pharmaceuticals' Prulifloxacin Phase 3 Trial in Traveler's Diarrhea and Strain Typing Data from OPT-80 Study to be Presented at ICAAC/IDSA Annual Meeting

  Educational Symposium on Clostridium Difficile Infections Will Address Global Epidemic and Treatment Options SAN DIEGO -- Results from three studies related to Optimer Pharmaceuticals, Inc.'s (NASDAQ:OPTR) developmental product candidates will be presented at this year's joint meeting of the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy ICAAC/Infectious...

  Articles 2008-10-20

• U.S. Sales Communications Excellence: Resources, Structure and Processes to Optimize Pharmaceutical Sales Communications

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/07d8ce/u_s_sales_communi) has announced the addition of the "U.S. Sales Communications Excellence: Resources, Structure and Processes to Optimize Pharmaceutical Sales Communications" report to their offering. Sales force performance significantly impacts growth and bottom line results. The ability of senior management to effectively disseminate...

  Articles 2008-10-17

• Optimer Pharmaceuticals has leased 7,663 square feet of office space in Sorrento Towers North, 5355 Mira Sorrento Place in Sorrento Valley, from Trizec Sorrento Towers LLC

  Optimer Pharmaceuticals has leased 7,663 square feet of office space in Sorrento Towers North, 5355 Mira Sorrento Place in Sorrento Valley, from Trizec Sorrento Towers LLC. The property, leased for three years at $846,300, will be used for corporate offices. The lessee was represented by Jay Arnett and Deborah Hunkeler...

  Articles 2008-09-22

• Blue Vector VP of Business Development to Speak at LogiPharma 2008

  Panel Session to Focus on Optimizing Pharmaceutical Supply Chain Performance PALO ALTO, Calif. -- Blue Vector Systems today announced that Romen Kuloor, Blue Vector's vice president of business development, has been invited to participate in a panel session at LogiPharma 2008, a gathering of pharmaceutical and biotech industry...

  Articles 2008-09-10

• Optimer Pharmaceuticals to Present at Two Upcoming Investor Conferences

  SAN DIEGO -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the following investor conferences: * Canaccord Adams Anti-Infectives Conference on Tuesday, September 16, 2008 at 11:00 a.m. Eastern Time at the InterContinental Barclay Hotel, New York City. * 2008 UBS...

  Articles 2008-09-10

• Optimer Pharmaceuticals Completes Enrollment in Second Prulifloxacin Phase 3 Clinical Trial

  SAN DIEGO -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced that the company has completed enrollment in the second of two planned phase 3 clinical trials evaluating the safety and efficacy of Prulifloxacin for the treatment of infectious diarrhea in travelers. The Company previously reported positive top-line data from the first...

  Articles 2008-09-02

• Research and Markets: Available Now - Optimer Pharmaceuticals Inc: Premium Company Profile

  DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/research/8dc894/optimer_pharmaceut) has announced the addition of the "Optimer Pharmaceuticals Inc: Premium Company Profile" company profile to their offering. Optimer is a biopharmaceutical company focused on the discovery, development and global commercialization of anti-infective products for the treatment of serious infectious diseases. The...

  Articles 2008-09-01

• Optimer Pharmaceuticals to Present at BioCentury NewsMakers Conference

  SAN DIEGO -- Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced today that the Company is scheduled to present on Thursday, September 4, 2008, at 1:30 p.m. ET at the NewsMakers in the Biotech Industry Conference at the Millennium Broadway Hotel in New York, NY. A live audio webcast of...

  Articles 2008-08-28

• Optimer Pharmaceuticals Reports Second Quarter 2008 Financial Results

  SAN DIEGO -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced its financial results for the second quarter ended June 30, 2008. Optimer reported a net loss for the second quarter of 2008 of $8.1 million, or $0.29 per share, compared to a net loss of $8.1 million, or $0.35 per share,...

  Articles 2008-08-06

• Optimer Pharmaceuticals to Present at August 2008 Investor Conferences

  SAN DIEGO -- Optimer Pharmaceuticals, Inc. (NASDAQ: OPTR) today announced that the Company will present at the following investor conferences: * BMO Capital Markets 2008 Focus on Healthcare Conference on Tuesday, August 5, 2008 at 4:00 p.m. Eastern Time at the Millennium Broadway Hotel, New York City. ...

  Articles 2008-07-30

• Optimer Pharmaceuticals Completes $14.8 Million Registered Direct Offering

  SAN DIEGO -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced that it completed a registered direct offering of 1,743,396 shares of common stock at a price of $8.48 per share, for total gross proceeds of $14.8 million. The closing involved the previously announced sale of 1,443,396 shares of Optimer's common stock...

  Articles 2008-07-28

• Optimer Pharmaceuticals Completes Enrollment in OPT-80 Phase 3 Clinical Trial in Patients with Clostridium difficile Infection

  SAN DIEGO -- Optimer Pharmaceuticals, Inc. (Nasdaq:OPTR) today announced that the company has completed enrollment in the first of two pivotal Phase 3 clinical trials evaluating the safety and efficacy of OPT-80 for the treatment of Clostridium difficile infection, or CDI. "Currently, there are limited treatment options for...

  Articles 2008-07-23